Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven australian hospitals.
Steinberg, J
Chan, P
Hogden, E
Tiernan, G
Morrow, A
Kang, Y-J
He, E
Venchiarutti, R
Titterton, L
Sankey, L
Pearn, A
Nichols, C
McKay, S
Hayward, A
Egoroff, N
Engel, A
Gibbs, P
Goodwin, A
Harris, M
Kench, JG
Pachter, N
Parkinson, B
Pockney, P
Ragunathan, A
Smyth, C
Solomon, M
Steffens, D
Toh, JWT
Wallace, M
Canfell, K
Gill, A
Macrae, F
Tucker, K
Taylor, N
- Publisher:
- Springer Science and Business Media LLC
- Publication Type:
- Journal Article
- Citation:
- Hered Cancer Clin Pract, 2022, 20, (1), pp. 18
- Issue Date:
- 2022-05-04
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
| Field | Value | Language |
|---|---|---|
| dc.contributor.author | Steinberg, J | |
| dc.contributor.author | Chan, P | |
| dc.contributor.author | Hogden, E | |
| dc.contributor.author | Tiernan, G | |
| dc.contributor.author | Morrow, A | |
| dc.contributor.author | Kang, Y-J | |
| dc.contributor.author | He, E | |
| dc.contributor.author | Venchiarutti, R | |
| dc.contributor.author | Titterton, L | |
| dc.contributor.author | Sankey, L | |
| dc.contributor.author | Pearn, A | |
| dc.contributor.author | Nichols, C | |
| dc.contributor.author | McKay, S | |
| dc.contributor.author | Hayward, A | |
| dc.contributor.author | Egoroff, N | |
| dc.contributor.author | Engel, A | |
| dc.contributor.author | Gibbs, P | |
| dc.contributor.author | Goodwin, A | |
| dc.contributor.author | Harris, M | |
| dc.contributor.author | Kench, JG | |
| dc.contributor.author | Pachter, N | |
| dc.contributor.author | Parkinson, B | |
| dc.contributor.author | Pockney, P | |
| dc.contributor.author | Ragunathan, A | |
| dc.contributor.author | Smyth, C | |
| dc.contributor.author | Solomon, M | |
| dc.contributor.author | Steffens, D | |
| dc.contributor.author | Toh, JWT | |
| dc.contributor.author | Wallace, M | |
| dc.contributor.author | Canfell, K | |
| dc.contributor.author | Gill, A | |
| dc.contributor.author | Macrae, F | |
| dc.contributor.author | Tucker, K | |
| dc.contributor.author | Taylor, N | |
| dc.date.accessioned | 2022-11-02T04:01:49Z | |
| dc.date.available | 2022-04-10 | |
| dc.date.available | 2022-11-02T04:01:49Z | |
| dc.date.issued | 2022-05-04 | |
| dc.identifier.citation | Hered Cancer Clin Pract, 2022, 20, (1), pp. 18 | |
| dc.identifier.issn | 1731-2302 | |
| dc.identifier.issn | 1897-4287 | |
| dc.identifier.uri | http://hdl.handle.net/10453/163147 | |
| dc.description.abstract | BACKGROUND: To inform effective genomic medicine strategies, it is important to examine current approaches and gaps in well-established applications. Lynch syndrome (LS) causes 3-5% of colorectal cancers (CRCs). While guidelines commonly recommend LS tumour testing of all CRC patients, implementation in health systems is known to be highly variable. To provide insights on the heterogeneity in practice and current bottlenecks in a high-income country with universal healthcare, we characterise the approaches and gaps in LS testing and referral in seven Australian hospitals across three states. METHODS: We obtained surgery, pathology, and genetics services data for 1,624 patients who underwent CRC resections from 01/01/2017 to 31/12/2018 in the included hospitals. RESULTS: Tumour testing approaches differed between hospitals, with 0-19% of patients missing mismatch repair deficiency test results (total 211/1,624 patients). Tumour tests to exclude somatic MLH1 loss were incomplete at five hospitals (42/187 patients). Of 74 patients with tumour tests completed appropriately and indicating high risk of LS, 36 (49%) were missing a record of referral to genetics services for diagnostic testing, with higher missingness for older patients (0% of patients aged ≤ 40 years, 76% of patients aged > 70 years). Of 38 patients with high-risk tumour test results and genetics services referral, diagnostic testing was carried out for 25 (89%) and identified a LS pathogenic/likely pathogenic variant for 11 patients (44% of 25; 0.7% of 1,624 patients). CONCLUSIONS: Given the LS testing and referral gaps, further work is needed to identify strategies for successful integration of LS testing into clinical care, and provide a model for hereditary cancers and broader genomic medicine. Standardised reporting may help clinicians interpret tumour test results and initiate further actions. | |
| dc.format | Electronic | |
| dc.language | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Hered Cancer Clin Pract | |
| dc.relation.isbasedon | 10.1186/s13053-022-00225-1 | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | 1112 Oncology and Carcinogenesis | |
| dc.subject.classification | Oncology & Carcinogenesis | |
| dc.title | Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven australian hospitals. | |
| dc.type | Journal Article | |
| utslib.citation.volume | 20 | |
| utslib.location.activity | Poland | |
| utslib.for | 1112 Oncology and Carcinogenesis | |
| pubs.organisational-group | /University of Technology Sydney | |
| pubs.organisational-group | /University of Technology Sydney/Faculty of Business | |
| pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
| pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Centre for Health Economics Research and Evaluation | |
| utslib.copyright.status | open_access | * |
| dc.date.updated | 2022-11-02T04:01:40Z | |
| pubs.issue | 1 | |
| pubs.publication-status | Published online | |
| pubs.volume | 20 | |
| utslib.citation.issue | 1 |
Abstract:
BACKGROUND: To inform effective genomic medicine strategies, it is important to examine current approaches and gaps in well-established applications. Lynch syndrome (LS) causes 3-5% of colorectal cancers (CRCs). While guidelines commonly recommend LS tumour testing of all CRC patients, implementation in health systems is known to be highly variable. To provide insights on the heterogeneity in practice and current bottlenecks in a high-income country with universal healthcare, we characterise the approaches and gaps in LS testing and referral in seven Australian hospitals across three states. METHODS: We obtained surgery, pathology, and genetics services data for 1,624 patients who underwent CRC resections from 01/01/2017 to 31/12/2018 in the included hospitals. RESULTS: Tumour testing approaches differed between hospitals, with 0-19% of patients missing mismatch repair deficiency test results (total 211/1,624 patients). Tumour tests to exclude somatic MLH1 loss were incomplete at five hospitals (42/187 patients). Of 74 patients with tumour tests completed appropriately and indicating high risk of LS, 36 (49%) were missing a record of referral to genetics services for diagnostic testing, with higher missingness for older patients (0% of patients aged ≤ 40 years, 76% of patients aged > 70 years). Of 38 patients with high-risk tumour test results and genetics services referral, diagnostic testing was carried out for 25 (89%) and identified a LS pathogenic/likely pathogenic variant for 11 patients (44% of 25; 0.7% of 1,624 patients). CONCLUSIONS: Given the LS testing and referral gaps, further work is needed to identify strategies for successful integration of LS testing into clinical care, and provide a model for hereditary cancers and broader genomic medicine. Standardised reporting may help clinicians interpret tumour test results and initiate further actions.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph